Assessment of adverse events in relation to age
11,009 patients in the 14 Phase II / III trials in OA and RA
4073 (37%) yr; 2366 on celecoxib
Celecoxib treated older age groups showed same tolerability profile as young population and better than NSAID comparator (4% vs 9.2% incidence of abdominal pain in North American arthritis trials)